1 published article · Updated continuously
9 trials tracked for Hallux Valgus: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 18 citations.
Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
For pain management after hallux valgus surgery, bupivacaine liposome injectable suspension 266 mg significantly reduced NRS pain scores and opioid consumption through 96 hours post-surgery compared to placebo (p<0.00001 for both), and increased the proportion of opioid-free subjects (33.3% vs 4.5%, p=0.0003) 2. Tapentadol IR 50 mg also demonstrated significant pain relief, with superior Sum of Pain Intensity Difference (SPID) over 48 hours versus placebo in multiple phase 3 trials (p<0.001 to p=0.006) 346. Response rates for ≥30% and ≥50% pain reduction were significantly higher with tapentadol 34.
In contrast, NaCl 0.9% (placebo) showed no significant difference in average or peak postoperative NRS pain scores (p=0.596 and p=0.353, respectively) and similar AOFAS scores (75.8 vs 75.7) in a phase 4 trial 1. No other established interventions for hallux valgus were identified from the provided trials.
AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
